VERX Stock Recent News

Vertex, Inc. (NASDAQ:VERX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David DeStefano - CEO, President & Chairman of the Board John R. Schwab - Chief Financial Officer Joseph J.

Although the revenue and EPS for Vertex (VERX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.

KING OF PRUSSIA, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2025.

Vertex Pharmaceuticals (VRTX -20.61%) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday.

Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.

Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.

CNBC's Angelica Peebles reports on Vertex Pharmaceuticals latest earnings report, including announcements that its CSO plans to retire August 2026.

Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.